[Federal Register: May 19, 2003 (Volume 68, Number 96)]
[Notices]
[Page 27093-27094]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19my03-75]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Biological Response Modifiers Advisory Committee; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). At least one
portion of the meeting will be closed to the public.
Name of Committee: Biological Response Modifiers Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on June 9, 2003, from 1
p.m. to approximately 3:30 p.m.
Location: National Institutes of Health, Bldg. 29A, rm. 1A09, 29
Lincoln Dr., Bethesda, MD. This meeting will be held by a telephone
conference call. Members of the public attending the meeting may
participate during the open session of the meeting at the specified
location.
Contact Person: Gail Dapolito or Rosanna L. Harvey, Center for
Biologics Evaluation and Research (HFM-71), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314,
or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-
0572 in the Washington, DC area), code 12389. Please call the
Information Line for up-to-date information on this meeting.
Agenda: On June 9, 2003, the committee will receive an update on
individual research programs in the Division of Cellular and Gene
Therapies.
Procedure: On June 9, 2003, from 1 p.m. to approximately 3 p.m.,
the meeting is open to the public. Interested persons may present data,
information, or views, orally or in writing, on issues pending before
the committee. Written submissions may be made to the contact person by
June 2, 2003. Oral presentations from the public will be scheduled
between approximately 2 p.m. and 3 p.m. Time allotted for each
presentation may be limited. Those desiring to make formal oral
presentations should notify the contact person before June 2, 2003, and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation.
Closed Committee Deliberations: On June 9, 2003, from approximately
3 p.m. to 3:30 p.m., the meeting will be closed to permit discussion
where disclosure would constitute a clearly unwarranted invasion of
personal privacy (5 U.S.C. 552b(c)(6)). The committee will discuss a
review of individual research programs in the Center for Biologics
Evaluation and Research.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you
[[Page 27094]]
require special accommodations due to a disability, please contact Gail
Dapolito at least 7 days in advance of the meeting.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: May 8, 2003.
Peter J. Pitts,
Associate Commissioner for External Relations.
[FR Doc. 03-12367 Filed 5-16-03; 8:45 am]
BILLING CODE 4160-01-S